Description

INVEGA SUSTENNA INJ 100 MG

Indications

INVEGA SUSTENNA (paliperidone palmitate) is an atypical antipsychotic indicated for the treatment of schizophrenia in adults. It is also approved for the treatment of schizoaffective disorder, which is characterized by the presence of both mood disorder and schizophrenia symptoms. The formulation is designed for intramuscular injection, providing a long-acting alternative for patients who may benefit from reduced dosing frequency compared to oral antipsychotics.

Mechanism of Action

Paliperidone, the active ingredient in INVEGA SUSTENNA, is an antagonist at multiple neurotransmitter receptors in the brain, including dopamine D2 and serotonin 5-HT2A receptors. This dual action is believed to contribute to its efficacy in managing symptoms of schizophrenia and schizoaffective disorder. By modulating dopaminergic and serotonergic activity, paliperidone helps to restore the balance of neurotransmitters, which can alleviate psychotic symptoms such as hallucinations, delusions, and disorganized thinking.

Pharmacological Properties

INVEGA SUSTENNA exhibits a pharmacokinetic profile characterized by a prolonged release of paliperidone into the bloodstream following intramuscular injection. The formulation is designed for once-monthly administration, allowing for steady plasma levels of the drug. Peak plasma concentrations are typically reached within 24 to 48 hours post-injection. The drug is primarily metabolized in the liver and excreted through the kidneys, with a half-life of approximately 25 to 49 hours. This pharmacological profile supports the management of chronic conditions such as schizophrenia, where consistent therapeutic levels are crucial for efficacy.

Contraindications

INVEGA SUSTENNA is contraindicated in patients with a known hypersensitivity to paliperidone or any of the excipients in the formulation. Additionally, it should not be used in patients with a history of severe cardiovascular events or those with a significant risk of developing tardive dyskinesia. Caution should be exercised in patients with a history of seizures, as the drug may lower the seizure threshold.

Side Effects

The use of INVEGA SUSTENNA may be associated with several side effects. Commonly reported adverse reactions include:

• Extrapyramidal symptoms (EPS), such as tremors, rigidity, and akathisia
• Weight gain
• Somnolence or sedation
• Insomnia
• Increased prolactin levels, which may lead to galactorrhea or menstrual irregularities
• Metabolic changes, including hyperglycemia and dyslipidemia

Serious side effects may include neuroleptic malignant syndrome (NMS), which is a life-threatening condition characterized by muscle rigidity, fever, autonomic instability, and altered mental status. Patients should be monitored closely for any signs of these adverse effects, especially during the initiation of therapy.

Dosage and Administration

INVEGA SUSTENNA is administered as an intramuscular injection, typically in the deltoid or gluteal muscle. The recommended starting dose for adults with schizophrenia is 234 mg on day one, followed by 156 mg on day eight. After the initial doses, the maintenance dose is 100 mg once monthly. Dosage adjustments may be necessary based on clinical response and tolerability. It is essential to follow the prescribed regimen and not to exceed the recommended doses to minimize the risk of adverse effects.

Interactions

INVEGA SUSTENNA may interact with other medications, which can alter its effectiveness or increase the risk of side effects. Caution is advised when co-administering with other central nervous system (CNS) depressants, such as benzodiazepines or alcohol, as these may enhance sedative effects. Additionally, medications that affect the CYP2D6 enzyme may influence paliperidone metabolism, potentially leading to altered plasma levels. It is crucial for healthcare providers to review all medications a patient is taking to prevent potential interactions.

Precautions

Before initiating treatment with INVEGA SUSTENNA, a thorough medical history should be obtained, and a physical examination conducted. Special precautions should be taken in patients with a history of cardiovascular disease, diabetes, or metabolic syndrome. Regular monitoring of weight, blood glucose, and lipid levels is recommended to detect any metabolic changes early. Patients should be advised to report any unusual symptoms promptly, including signs of infection, as paliperidone may increase the risk of agranulocytosis in susceptible individuals.

Clinical Studies

Clinical trials have demonstrated the efficacy of INVEGA SUSTENNA in reducing the symptoms of schizophrenia and schizoaffective disorder. In a pivotal study, patients receiving INVEGA SUSTENNA showed significant improvement in the Positive and Negative Syndrome Scale (PANSS) scores compared to those receiving placebo. Long-term studies have also indicated that the extended-release formulation is effective in maintaining symptom control over extended periods, with a favorable safety profile compared to other antipsychotic medications.

Conclusion

INVEGA SUSTENNA is a valuable treatment option for adults with schizophrenia and schizoaffective disorder, offering the convenience of once-monthly administration. Its unique mechanism of action, combined with a favorable pharmacokinetic profile, supports its role in managing these chronic mental health conditions. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Ongoing monitoring and patient education play critical roles in optimizing treatment outcomes with INVEGA SUSTENNA.